Repligen (NASDAQ:RGEN) Upgraded to "Hold" at StockNews.com

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Monday.

Several other research analysts also recently commented on the company. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $176.82.

Repligen Stock Performance

RGEN stock traded down $1.12 during trading on Monday, reaching $143.63. The stock had a trading volume of 862,327 shares, compared to its average volume of 712,709. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The stock's 50 day moving average is $139.66 and its two-hundred day moving average is $145.97. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.06 billion, a PE ratio of -281.63, a PEG ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. As a group, equities analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Repligen

Large investors have recently bought and sold shares of the business. Signaturefd LLC increased its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in Repligen during the fourth quarter valued at $29,000. Raiffeisen Bank International AG bought a new position in Repligen during the fourth quarter valued at $29,000. Itau Unibanco Holding S.A. bought a new position in Repligen during the fourth quarter valued at $40,000. Finally, UMB Bank n.a. increased its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.